Chemistry:Lithium cocrystal
 | |
 Lithium salicylate (top) and L-proline (bottom) | |
| Combination of | |
|---|---|
| Lithium salicylate | Lithium salt |
| L-Proline | Amino acid |
| Clinical data | |
| Trade names | AL-001, Lithium salicylate/L-proline cocrystal, LiProSal, LISPRO |
| Routes of administration | oral |
| Drug class | Mood stabilizer |
Lithium cocrystal (AL-001, Lithium salicylate/L-proline cocrystal, LiProSal, LISPRO) is a form of lithium that combines lithium salicylate and the amino acid L-proline.[1][2] The ionic cocrystal (ICC) form combines the lithium salt with an organic anion.[3][4] This formulation allows more of the compound to cross the blood brain barrier and into the central nervous system.[5] The lithium salicylate/L-proline cocrystal allows approximately 20% lower blood serum levels versus lithium carbonate, and thus fewer attendant side effects.[6][7] The compound is in phase 2 clinical trials for Alzheimer's disease, bipolar disorder, major depressive disorder and PTSD.[8] Lithium cocrystal was created in 2004 at the University of South Florida.[6] It is under development by Alzamend Neuro with the designation AL-001.[8][9][10]
See also
References
- ↑ PubChem. "Lithium Salicylate" (in en). https://pubchem.ncbi.nlm.nih.gov/compound/23663621.
- ↑ Li, Yanping; Chen, Hua; Lai, Jimin; Huang, Xinlan; Leng, Guangjian; Zhang, Haoran; Lin, Zehong; Liu, Jitao et al. (2024-11-05). "Novel lithium ionic cocrystals with benzoic acid derivatives and L-proline: Synthesis, X-ray structures, IR spectrums, DSC analysis, and water solubility". Journal of Molecular Structure 1315. doi:10.1016/j.molstruc.2024.138795. ISSN 0022-2860. https://www.sciencedirect.com/science/article/pii/S0022286024013140.
- ↑ Smith, Adam J.; Kim, Seol-Hee; Duggirala, Naga K.; Jin, Jingji; Wojtas, Lukasz; Ehrhart, Jared; Giunta, Brian; Tan, Jun et al. (2013-12-02). "Improving lithium therapeutics by crystal engineering of novel ionic cocrystals". Molecular Pharmaceutics 10 (12): 4728–4738. doi:10.1021/mp400571a. ISSN 1543-8392. PMID 24191685.
- ↑ Sanii, Rana; Andaloussi, Yassin H.; Patyk-Kaźmierczak, Ewa; Zaworotko, Michael J. (2022-06-01). "Polymorphism in Ionic Cocrystals Comprising Lithium Salts and l-Proline". Crystal Growth & Design 22 (6): 3786–3794. doi:10.1021/acs.cgd.2c00172. ISSN 1528-7483. PMID 36160301.
- ↑ Habib, Ahsan; Shytle, R. Douglas; Sawmiller, Darrell; Koilraj, Selina; Munna, Sadia Afrin; Rongo, David; Hou, Huayan; Borlongan, Cesario V. et al. (1 September 2019). "Comparing the effect of the novel ionic cocrystal of lithium salicylate proline (LISPRO) with lithium carbonate and lithium salicylate on memory and behavior in female APPswe/PS1dE9 Alzheimer's mice". Journal of Neuroscience Research 97 (9): 1066–1080. doi:10.1002/jnr.24438. ISSN 1097-4547. PMID 31102295.
- ↑ 6.0 6.1 "Lithium: 12 Updates from 2023 | CARLAT PUBLISHING" (in en). https://www.thecarlatreport.com/blogs/2-the-carlat-psychiatry-podcast/post/4584-a-new-form-of-lithium.
- ↑ Lobo, Andrea (2024-09-04). "New partners for Phase 2 trial of next-gen lithium therapy AL001" (in en-US). https://alzheimersnewstoday.com/news/new-partners-phase-2-trial-next-gen-lithium-therapy-al001/.
- ↑ 8.0 8.1 "Lithium cocrystal - Alzamend Neuro - AdisInsight". https://adisinsight.springer.com/drugs/800058554.
- ↑ Cummings, Jeffrey L.; Osse, Amanda M. Leisgang; Kinney, Jefferson W. (1 Oct 2023). "Alzheimer's Disease: Novel Targets and Investigational Drugs for Disease Modification". Drugs 83 (15): 1387–1408. doi:10.1007/s40265-023-01938-w. ISSN 1179-1950. PMID 37728864.
- ↑ "Next-generation lithium treatment for bipolar disorder to be studied" (in en). https://www.healio.com/news/psychiatry/20231009/nextgeneration-lithium-treatment-for-bipolar-disorder-to-be-studied.
 |  |
